Literature DB >> 17446348

Flt3-dependent transformation by inactivating c-Cbl mutations in AML.

Bülent Sargin1, Chunaram Choudhary, Nicola Crosetto, Mirko H H Schmidt, Rebekka Grundler, Marion Rensinghoff, Christine Thiessen, Lara Tickenbrock, Joachim Schwäble, Christian Brandts, Benjamin August, Steffen Koschmieder, Srinivasa Rao Bandi, Justus Duyster, Wolfgang E Berdel, Carsten Müller-Tidow, Ivan Dikic, Hubert Serve.   

Abstract

In acute myeloid leukemia (AML), mutational activation of the receptor tyrosine kinase (RTK) Flt3 is frequently involved in leukemic transformation. However, little is known about a possible role of highly expressed wild-type Flt3 in AML. The proto-oncogene c-Cbl is an important regulator of RTK signaling, acting through its ubiquitin ligase activity and as a platform for several signaling adaptor molecules. Here, we analyzed the role of c-Cbl in Flt3 signal transduction and myeloid transformation. C-Cbl physically interacted with Flt3 and was tyrosine phosphorylated in the presence of Flt3-ligand (FL). Overexpression of a dominant-negative form of c-Cbl (Cbl-70Z) inhibited FL-induced Flt3 ubiquitylation and internalization, indicating involvement of c-Cbl in Flt3 signaling. DNA sequencing of AML bone marrow revealed a case with a c-Cbl point mutation (Cbl-R420Q). Cbl-R420Q inhibited Flt3 internalization and ubiquitylation. Coexpression of Cbl-R420Q or Cbl-70Z with Flt3 induced cytokine-independent growth and survival of 32Dcl3 cells in the absence of FL. Also, the mutant Cbl proteins altered the amplitude and duration of Flt3-dependent signaling events. Our results indicate an important role of Cbl proteins in Flt3 signal modulation. Also, the data suggest a novel mechanism of leukemic transformation in AML by mutational inactivation of negative RTK regulators.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17446348     DOI: 10.1182/blood-2007-01-066076

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  80 in total

Review 1.  Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.

Authors:  Stephen C Kales; Philip E Ryan; Marion M Nau; Stanley Lipkowitz
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.

Authors:  Scott A Nadeau; Wei An; Bhopal C Mohapatra; Insha Mushtaq; Timothy A Bielecki; Haitao Luan; Neha Zutshi; Gulzar Ahmad; Matthew D Storck; Masashi Sanada; Seishi Ogawa; Vimla Band; Hamid Band
Journal:  J Biol Chem       Date:  2017-01-12       Impact factor: 5.157

3.  Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins.

Authors:  Scott Nadeau; Wei An; Nick Palermo; Dan Feng; Gulzar Ahmad; Lin Dong; Gloria E O Borgstahl; Amarnath Natarajan; Mayumi Naramura; Vimla Band; Hamid Band
Journal:  Biochem Anal Biochem       Date:  2012-07-30

4.  Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.

Authors:  Yuka Saito; Yoko Aoki; Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski; Masue Imaizumi; Takeshi Rikiishi; Yoji Sasahara; Shigeo Kure; Tetsuya Niihori; Shigeru Tsuchiya; Seiji Kojima; Yoichi Matsubara
Journal:  Leuk Res       Date:  2012-05-14       Impact factor: 3.156

5.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

6.  250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.

Authors:  Andrew J Dunbar; Lukasz P Gondek; Christine L O'Keefe; Hideki Makishima; Manjot S Rataul; Hadrian Szpurka; Mikkael A Sekeres; Xiao Fei Wang; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.

Authors:  Michael A Caligiuri; Roger Briesewitz; Jianhua Yu; Lisheng Wang; Min Wei; Kristy J Arnoczky; Trent B Marburger; Jing Wen; Danilo Perrotti; Clara D Bloomfield; Susan P Whitman
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

8.  Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl.

Authors:  Christopher Slape; Leah Y Liu; Sarah Beachy; Peter D Aplan
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

9.  Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

Authors:  Hideki Makishima; Heather Cazzolli; Hadrian Szpurka; Andrew Dunbar; Ramon Tiu; Jungwon Huh; Hideki Muramatsu; Christine O'Keefe; Eric Hsi; Ronald L Paquette; Seiji Kojima; Alan F List; Mikkael A Sekeres; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

10.  FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.

Authors:  Julhash U Kazi; Lars Rönnstrand
Journal:  Mol Oncol       Date:  2012-11-29       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.